J. Walz to Risk Factors
This is a "connection" page, showing publications J. Walz has written about Risk Factors.
Connection Strength
0.241
-
Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol. 2009 Feb; 55(2):412-19.
Score: 0.037
-
Walz J, Shariat SF, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
Score: 0.036
-
Memtsoudis SG, Rosenberger P, Walz JM. Critical care issues in the patient after major joint replacement. J Intensive Care Med. 2007 Mar-Apr; 22(2):92-104.
Score: 0.033
-
Walz JM, Paterson CA, Seligowski JM, Heard SO. Surgical site infection following bowel surgery: a retrospective analysis of 1446 patients. Arch Surg. 2006 Oct; 141(10):1014-8; discussion 1018.
Score: 0.032
-
Bjerner J, Bratt O, Aas K, Albertsen PC, Foss? SD, Kv?le R, Lilja H, M?ller C, M?ller S, Stensvold A, Thomas O, R?e OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024 Jul; 86(1):20-26.
Score: 0.025
-
Regnier P, DE Luca V, Brunelle S, Sfumato P, Walz J, Rybikowski S, Maubon T, Branger N, Fakhfakh S, Durand M, Gravis G, Pignot G. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Minerva Urol Nephrol. 2021 04; 73(2):215-224.
Score: 0.020
-
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Eur Urol Focus. 2018 04; 4(3):369-375.
Score: 0.016
-
Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):319-25.
Score: 0.013
-
Memtsoudis S, Liu SS, Ma Y, Chiu YL, Walz JM, Gaber-Baylis LK, Mazumdar M. Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac surgery. Anesth Analg. 2011 Jan; 112(1):113-21.
Score: 0.011
-
Memtsoudis SG, Ma Y, Chiu YL, Walz JM, Voswinckel R, Mazumdar M. Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement. Anesth Analg. 2010 Nov; 111(5):1110-6.
Score: 0.010
-
Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, K?llermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur Urol. 2008 Apr; 53(4):750-7.
Score: 0.009